Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cornea Transplant Clear all
Terminated Phase 1 Interventional

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

NCT01868360
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Subconjunctival aflibercept, Placebo: Standard of care only
Drug · Other
Lead sponsor
Balamurali Ambati
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Phase 3 Interventional

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187
View directory record Official record
Conditions
Corneal Diseases, Cornea Transplant
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 6, 2026, 8:04 AM EDT
Recruiting Not applicable Interventional

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

NCT06261346
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Corneal Edema
Interventions
Endothelial keratoplasty, PRGF
Procedure · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Miami, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 6, 2026, 8:04 AM EDT
Completed No phase listed Observational

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

NCT04975971
View directory record Official record
Conditions
Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating KeratoPlasty, Nuclear Cataract, Cortical Cataract, Cataract Senile
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Not applicable Interventional Results available

Cornea Donor Study

NCT00006411
View directory record Official record
Conditions
Corneal Disease, Fuch's Dystrophy, Pseudophakic Corneal Edema
Interventions
corneas assigned by donor age group
Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
40 Years to 80 Years
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 1 Interventional

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

NCT00769145
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Ranibizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 110 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

NCT02592330
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
Procedure · Biological
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 6, 2026, 8:04 AM EDT
Withdrawn Phase 1 Interventional

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

NCT02042027
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions
Gamunex-C
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Results available

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

NCT05136443
View directory record Official record
Conditions
Corneal Endothelial Dystrophy, Corneal Edema
Interventions
loteprednol etabonate 0.25% ophthalmic suspension
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Not applicable Interventional Results available

Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

NCT00884039
View directory record Official record
Conditions
Transplant, Intraocular Pressure
Interventions
anecortave acetate, 30 mg anecortave acetate
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01072357
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 6, 2026, 8:04 AM EDT
Not listed Phase 4 Interventional Results available

Descemet Endothelial Thickness Comparison Trial

NCT02373137
View directory record Official record
Conditions
Keratoplasty, Grafting, Corneal, Transplantation, Corneal, Transplantation, Cornea, Keratoplasty, Lamellar
Interventions
DSAEK, DMEK, Endoserter, Prednisolone, Ofloxacin, Tropicamide, Phenylephrine, Jones Tube
Procedure · Device · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Palo Alto, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Not applicable Interventional

OCT-guided DSAEK Graft Shaping and Smoothing

NCT01586234
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
DSAEK with graft shaping and smoothing, Standard DSAEK
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 6, 2026, 8:04 AM EDT
Not yet recruiting No phase listed Observational

Intraoperative Optical Coherence Tomography for Ophthalmic Surgical Guidance - Cornea

NCT05210478
View directory record Official record
Conditions
Corneal Transplantation
Interventions
Optical coherence tomography (OCT)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Timeline
2027 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Phase 3 Interventional

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

NCT00447642
View directory record Official record
Conditions
Corneal Transplantation, Corneal Graft Rejection
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Results available

Cornea Preservation Time Study

NCT01537393
View directory record Official record
Conditions
Cornea Preservation Time, Endothelial Keratoplasty, Transplant Success, Endothelial Cell Density
Interventions
Cornea tissue transplant
Biological
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 90 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
40
States / cities
Beverly Hills, California • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Not applicable Interventional

A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema

NCT00346138
View directory record Official record
Conditions
Fuchs Dystrophy, Corneal Edema
Interventions
Corneal transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01996826
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Not applicable Interventional

Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

NCT05809245
View directory record Official record
Conditions
Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
Interventions
Corneal neurotization
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

NCT02040623
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution
Drug · Other
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Plantation, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Not applicable Interventional Results available

Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss

NCT05134480
View directory record Official record
Conditions
Corneal Endothelial Decompensation, Fuchs' Endothelial Dystrophy
Interventions
Descemet membrane endothelial keratoplasty
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 90 Years
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 6, 2026, 8:04 AM EDT
Not listed Phase 4 Interventional

Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)

NCT01357122
View directory record Official record
Conditions
Fuchs' Corneal Endothelial Dystrophy
Interventions
NCI Insertion, Standard Forceps Insertion
Device · Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Sep 6, 2026, 8:04 AM EDT